Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Mesylate Combined With Toripalimab in Stage III/IV Melanoma With CKIT Mutation
NCT05274438Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2021
- Primary completion
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and imatinib in melanoma, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
toripalimabimatinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05274438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274438.